SANCUSO 3. 1 mg/2. Summary of Product Characteristics (SPC)SANCUSO 3. Each 5. 2 cm. 2 transdermal patch contains 3. Bula do canada buy granisetron kytril iv cost difference between and ondansetron. Melting point bcs classification granisetron oral dosage tbl patch patent. For the full list of excipients, see section 6. Transdermal patch. Thin, translucent, matrix- type, rectangular- shaped transdermal patch with rounded corners. SANCUSO transdermal patch is indicated in adults for the prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy, for a planned duration of 3 to 5 consecutive days, where oral anti- emetic administration is complicated by factors making swallowing difficult (see section 5. Posology. Adults. Apply a single transdermal patch 2. Due to a gradual increase in plasma levels of granisetron following application of the transdermal patch, a slower onset of efficacy compared to 2 mg oral granisetron may be observed at the start of chemotherapy; the patch should be applied 2. The transdermal patch should be removed a minimum of 2. The transdermal patch can be worn for up to 7 days depending on the duration of the chemotherapy regimen. Following routine haematological monitoring, the transdermal patch should only be applied to patients whose chemotherapy treatment is unlikely to be delayed in order to reduce the possibility of unnecessary exposure to granisetron. Use of concomitant corticosteroids. The Multinational Association of Supportive Care in Cancer (MASCC) guidelines recommend the administration of dexamethasone with 5. HT3 antagonist prior to chemotherapy. In the pivotal SANCUSO study, the concomitant use of corticosteroids, e. Any increase in corticosteroid use during the study was reported as rescue treatment. Special populations. Older people. Dosing as for adults (see sections 4. Renal or hepatic impairment. No dose adjustment is necessary. Dosing as for adults (see sections 4. Transdermal Patch Tailors Antinausea Treatment. The granisetron patch was applied 24 to 48 hours before the first dose of chemotherapy. Aspen side effects hydrochloride cas granisetron patch cost difference between zofran medikament. Article 30 patch cost kytril kullan. Hydrochloride 1 mg ap pharma kytril availability generic drug. Although no evidence of an increased incidence of adverse reactions have been observed in patients with renal or hepatic impairment receiving granisetron orally and intravenously, based on granisetron pharmacokinetics, a degree of caution must be exercised in this population. Paediatric population. The safety and efficacy of SANCUSO in children aged 0 to 1. No data are available. Method of administration. The transdermal patch should be applied to clean, dry, intact healthy skin on the outer part of the upper arm. If it is not possible to apply the transdermal patch to the arm, it can be applied to the abdomen. The transdermal patch should not be placed on skin that is red, irritated or damaged. Each transdermal patch is packed in a sachet and should be applied directly after the sachet has been opened. The release liner is removed prior to application. The transdermal patch should not be cut into pieces. In the event of a transdermal patch becoming completely or partially detached, the original transdermal patch should be reattached in the same position using medical tape (if necessary). Cost Comparisons: 5-HT. Granisetron transdermal patch. Granisetron Hydrochloride Injection: liquid: 1 mg: intravenous: Sandoz Canada Incorporated: 2009-02-20: Not applicable: Canada. Cost Unit; Sancuso 3.1 mg/24 hr patch: 372.0USD : patch: Kytril 2 1 mg tablet Box: 131.98USD. Dose children sancuso patch granisetron embarazo kytril granisetron price medicamento. Iv cost chemical structure granisetron hydrochloride drug bank via oral wirkung. Tablets package insert plm injection + dailymed pbs. If reattachment is not possible or the transdermal patch is damaged, a new transdermal patch should be applied in the same position as the original transdermal patch. If this is not possible, a new transdermal patch should be applied on the opposite arm. The newly applied transdermal patch should be removed in line with the timing recommended above. Hypersensitivity to the active substance, to other 5- HT3 receptor antagonists or to any of the excipients listed in section 6. Application site reactions. In clinical trials with SANCUSO, application site reactions were reported which were generally mild in intensity and did not lead to discontinuation of use. If severe reactions, or a generalised skin reaction occur (e. This potentially may have clinical significance in patients with pre- existing arrhythmias or cardiac conduction disorders or patients who are being treated with antiarrhythmics or beta- blockers. No clinically relevant effects have been observed in clinical studies with SANCUSO. Exposure to sunlight. Granisetron may be affected by direct natural or artificial sunlight. Patients must be advised to cover the transdermal patch application site, e. Activities such as swimming, strenuous exercise or using a sauna should be avoided. External heat. External heat (for example hot water bottles or heat pads) should be avoided on the area of the transdermal patch. Special populations. No dose adjustments are necessary for the elderly or patients with renal or hepatic impairment. Although no evidence of an increased incidence of adverse reactions have been observed in patients with renal or hepatic impairment receiving granisetron orally and intravenously, based on granisetron pharmacokinetics, a degree of caution must be exercised in this population. Serotonin syndrome. There have been reports of serotonin syndrome with the use of 5- HT3 antagonists either alone, but mostly in combination with other serotonergic drugs (including selective serotonin reuptake inhibitors (SSRIs), and serotonin noradrenaline reuptake inhibitors (SNRIs). Appropriate observation of patients for serotonin syndrome- like symptoms is advised. In vitro studies using human microsomes indicate that granisetron neither stimulates nor inhibits the cytochrome P4. As granisetron is metabolised by hepatic cytochrome P4. CYP1. A1 and CYP3. A4), inducers or inhibitors of these enzymes may change the clearance and, hence, the half- life of granisetron. In human subjects, hepatic enzyme induction by phenobarbital has led to an increase in total plasma clearance (approximately 2. Co- administration of intravenous 5- HT3 receptor antagonists with oral paracetamol in human subjects has been reported to result in a block in the analgesic effect via a pharmacodynamic mechanism. In vitro studies have shown that ketoconazole may inhibit the metabolism of granisetron via the cytochrome P4. A isoenzyme family. The clinical significance of this is unknown. In studies in healthy subjects, no evidence of any interaction has been indicated between granisetron and benzodiazepines (lorazepam), neuroleptics (haloperidol) or anti- ulcer medicinal products (cimetidine). No clinically relevant drug interactions between SANCUSO and emetogenic cancer chemotherapies have been seen. Furthermore, no interaction has been observed between granisetron and emetogenic cancer therapies. In agreement with these data, no clinically relevant drug interactions have been reported in clinical studies with SANCUSO. In clinical interaction studies, aprepitant did not have clinically important effects on the pharmacokinetics of granisetron. Serotonergic Drugs (e. SSRIs and SNRIs): there have been reports of serotonin syndrome following concomitant use of 5- HT3 antagonists and other serotonergic drugs (including SSRIs and SNRIs). Paediatric population. Interaction studies have only been performed in adults. Pregnancy. There are no data on the use of granisetron in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5. As a precautionary measure, it is preferable to avoid the use of SANCUSO during pregnancy. Breast- feeding. It is unknown whether granisetron or its metabolites are excreted in human milk. Breast- feeding should be discontinued during treatment with SANCUSO. Fertility. There are no data on the effect of granisetron on human fertility. Fertility was unaffected following granisetron treatment in rats. SANCUSO has no or negligible influence on the ability to drive and use machines. Summary of the safety profile. The safety profile of SANCUSO is derived from controlled clinical trials and from post- marketing experience. The most commonly reported adverse reaction in clinical studies was constipation, occurring in approximately 8. The majority of adverse reactions were mild or moderate in severity. Tabulated list of adverse reactions. Adverse reactions from clinical studies and spontaneous reports with SANCUSO are listed in the table below: Within the system organ class, the adverse reactions are listed by frequency using the following convention: very common (. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via: the yellow card scheme. Website: www. mhra. There is no specific antidote for granisetron. In the event of overdose, the transdermal patch should be removed. Symptomatic treatment should be given. Pharmacotherapeutic group: Antiemetics and antinauseants, serotonin (5. HT3) antagonists ATC code: A0. AA0. 2Granisetron is a potent anti- emetic and highly selective antagonist of 5- hydroxytryptamine (5. HT3 receptors). Pharmacological studies have demonstrated that granisetron is effective against nausea and vomiting as a result of cytostatic therapy. Radioligand binding studies have demonstrated that granisetron has negligible affinity for other receptor types, including 5. HT1, 5. HT2, 5. HT4 and dopamine D2 binding sites. A pivotal, randomised, double- blind, double- dummy, multinational Phase III study compared the efficacy, tolerability and safety of SANCUSO with that of 2 mg oral granisetron once daily in the prevention of nausea and vomiting in a total of 6. The study was designed to show non- inferiority of SANCUSO to oral granisetron. The population randomised into the trial included 4. ME) or highly emetogenic (HE) multi- day chemotherapy. Asian and 1. 0% Hispanic/Latino. The granisetron transdermal patch was applied 2. Oral granisetron was administered daily for the duration of the chemotherapy regimen, one hour prior to each dose of chemotherapy. Anti- emetic activity was assessed from the first administration until 2. ME or HE chemotherapy regimen. Non- inferiority of SANCUSO versus oral granisetron was confirmed, with complete control (CC) achieved in 6. SANCUSO arm and 6. CC was defined as no vomiting and/or retching, no more than mild nausea and no rescue medicine from the first administration until 2. Kytril - Other : : Internet Drogerie. INDICATIONSKytril blocks the actions of chemicals in the body that can trigger nausea and vomiting. INSTRUCTIONSTake Kytril exactly as it was prescribed for you. Do not take the medication in larger amounts, or take it for longer than recommended by your doctor. Follow the directions on your prescription label. Kytril is usually started up to 1 hour before chemotherapy. Follow your doctor's instructions. Measure the liquid form of Kytril with a special dose- measuring spoon or cup, not a regular table spoon. If you do not have a dose- measuring device, ask your pharmacist for one. If you missed a dose - tell your doctor if you forget to take your dose within 1 hour before chemotherapy. Do not take extra medicine to make up the missed dose. DOSAGEEmetogenic Chemotherapy. The recommended adult dosage of oral KYTRIL (granisetron hydrochloride) is 2 mg once daily or 1 mg twice daily. In the 2 mg once- daily regimen, two 1 mg tablets or 1. L of KYTRIL (granisetron) Oral Solution (2 teaspoonfuls, equivalent to 2 mg of granisetron) are given up to 1 hour before chemotherapy. In the 1 mg twice- daily regimen, the first 1 mg tablet or one teaspoonful (5 m. L) of KYTRIL (granisetron) Oral Solution is given up to 1 hour before chemotherapy, and the second tablet or second teaspoonful (5 m. L) of KYTRIL (granisetron) Oral Solution, 1. Either regimen is administered only on the day(s) chemotherapy is given. Continued treatment, while not on chemotherapy, has not been found to be useful. Pediatric Use. Safety and effectiveness in pediatric patients have not been established. Radiation (Either Total Body Irradiation or Fractionated Abdominal Radiation)The recommended adult dosage of oral KYTRIL (granisetron) is 2 mg once daily. Two 1 mg tablets or 1. L of KYTRIL (granisetron) Oral Solution (2 teaspoonfuls, equivalent to 2 mg of granisetron) are taken within 1 hour of radiation. STORAGEStore Kytril at room temperature away from moisture and heat. SAFETY INFORMATIONYou should not use Kytril if you are allergic to granisetron or to similar medicines such as dolasetron (Anzemet), ondansetron (Zofran), or palonosetron (Aloxi). Before taking Kytril, tell your doctor if you have liver disease, a heart rhythm disorder, an electrolyte imbalance (such as low levels of potassium or magnesium in your blood), or a personal or family history of Long QT syndrome. If you have any of these other conditions, you may need a dose adjustment or special tests to safely take Kytril: liver disease; a heart rhythm disorder; an electrolyte imbalance (such as low levels of potassium or magnesium in your blood); or a personal or family history of Long QT syndrome. FDA pregnancy category B. Kytril is not expected to be harmful to an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. It is not known whether granisetron passes into breast milk or if it could harm a nursing baby. Do not use Kytril without telling your doctor if you are breast- feeding a baby. Kytril is usually started up to 1 hour before chemotherapy. Tell your doctor if you forget to take the medication within the specified amount of time before your procedure. There may be other drugs that can interact with Kytril. Tell your doctor about all your prescription and over- the- counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor. SIDE EFFECTSGet emergency medical help if you have any of these signs of an allergic reaction to Kytril: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have a serious side effect such as: fast or pounding heartbeats; fever, body aches, flu symptoms; oreasy bruising or bleeding; unusual weakness. Less serious Kytril side effects may include: headache; stomach pain or upset, loss of appetite; diarrhea or constipation; dizziness; orsleep problems (insomnia). This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
December 2016
Categories |